

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: GRONHOJ-LARSEN, et al.
 Serial No.: 09/101,825
 Filed: July 17, 1998
 For: SYNTHETIC IL-10 ANALOGUES

Art Unit: 1646
 Examiner: HAMUD, F.
 Washington, D.C.
 Atty.'s Docket: GRONHOJ-LARSEN=2
 Date: December 21, 1999

THE COMMISSIONER OF PATENTS AND TRADEMARKS
 Washington, D.C. 20231

Sir:

Transmitted herewith is an [] Amendment [XX] Third Preliminary Amendment

in

the above-identified application.

[] Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.
 [] A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.
 [] No additional fee is required.

RECEIVED

DEC 27 1999

The fee has been calculated as shown below:

	(Col. 1)	(Col. 2)	(Col. 3)	Small Entity				TECH CENTER 1600/2900		
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra		Rate	Additional Fee		Rate	Additional Fee
Total	47	Minus	31	=16		x 9	\$		x18	\$288.00
Indep.	4	Minus	3	=1		x39	\$		x78	\$ 78.00
First Presentation of Multiple Dependent Claim						+130	\$		+260	\$
TOTAL ADDITIONAL CLAIMS FEE							\$	Total		\$366.00

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required applicant requests that this be considered a petition therefor.

[] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

[] First - \$ 55.00
 [] Second - \$190.00
 [] Third - \$435.00
 [] Fourth - \$680.00

Other Than Small Entity

Response Filed Within

[] First - \$ 110.00
 [] Second - \$ 380.00
 [] Third - \$ 870.00
 [] Fourth - \$1360.00

[] Less fees (\$) already paid for months extension of time on

[] Please charge my Deposit Account No. 02-4035 in the amount of \$. A duplicate copy of this sheet is attached.

[XX] A check in the amount of \$366.00 is attached (check no. 23781).

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR Section 1.16 and all patent processing fees under 37 CFR Section 1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR Section 1.18.

BROWDY AND NEIMARK
 Attorneys for Applicant(s)

By:

IVER P. COOPER
 Registration No. 28,005

Facsimile: (202) 737-3528
 Telephone: (202) 628-5197

*Patent Act C/11
1/17/99
01/15/00*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

) Art Unit: 1646

GRONHOJ-LARSEN, et al.

) Examiner: HAMUD, F.

Serial No.: 09/101,825


Washington, D.C.

Filed: July 17, 1998

December 21, 1999

For: SYNTHETIC IL-10
ANALOGUES

Docket No.: GRONHOJ-LARSEN=2



THIRD PRELIMINARY AMENDMENT

O I P E
Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

S i r :

Please add the following claims:

DW/T2
--49. A method of preventing or treating a disease which is preventable or treatable by a substance which has at least one of the following properties,

- a) induces inhibition of spontaneous IL-8 production by human monocytes,
- b) induces inhibition of IL-1 β induced IL-8 production by human peripheral blood mononuclear cells (PBMC),
- c) induces production of interleukin-1 receptor antagonistic protein (IRAP) by human monocytes,
- d) induces chemotactic migration of CD8+ human T lymphocytes in vitro,
- e) desensitizes human CD8+ T cells resulting in an unresponsiveness towards rhIL-10,
- f) suppresses the chemotactic response of CD4+ T human lymphocytes towards IL-8,
- g) suppresses the chemotactic response of human monocytes towards MCAF/MCP-1,
- h) inhibits class II MHC molecule expression on human monocytes stimulated by IFN- γ ,
- i) induces the production of IL-4 by cultured normal human CD4+ T cells,
- j) reduces the TNF α production in human mixed leukocyte

12/22/1999 RITSEGATE 000000011 09101825

288.00 0P
78.00 0P
01 FC:103
02 FC:102